To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

The Evolution of beta-Blo… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

The Evolution of beta-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)

Journal article
Authors P. Joseph
Karl Swedberg
D. P. Leong
S. Yusuf
Published in Journal of the American College of Cardiology
Volume 74
Issue 5
Pages 672-682
ISSN 0735-1097
Publication year 2019
Published at Institute of Medicine, Department of Molecular and Clinical Medicine
Pages 672-682
Language en
Links dx.doi.org/10.1016/j.jacc.2019.04.0...
Keywords beta-blockers, coronary artery disease, heart failure, preserved ejection fraction, acute myocardial-infarction, low-income, countries, cardiovascular-disease, clinical-outcomes, middle-income, bucindolol, mortality, trial, carvedilol, Cardiovascular System & Cardiology
Subject categories Cardiac and Cardiovascular Systems

Abstract

As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of beta-adrenergic receptor blockers (beta-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting beta-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. beta-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of beta-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. (C) 2019 by the American College of Cardiology Foundation.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?